Brief: Tempest gets FDA nod to begin mid-stage study of its therapy for colon cancer-causing genertic condition
13/03/2025 12:20
March 13 (Reuters) - Tempest Therapeutics Inc TPST.O: FDA STUDY MAY PROCEED NOTICE RECEIVED FOR PHASE 2 TRIAL OF TPST-1495 FOR THE TREATMENT OF FAMILIAL ADENOMATOUS POLYPOSIS (FAP) TEMPEST THERAPEUTICS INC - PHASE 2 STUDY TO ASSESS EFFICACY OF TPST-1495 IN FAP PATIENTS Source text: ID:nGNX78Cn3v Further company coverage: TPST.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tempest Therapeutics
See all newsBrief: Tempest Therapeutics - Justin Trojanowski To Resign As Principal Financial Officer And Principal Accounting Officer Effective Sept 1 - SEC Filing
Tempest Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Tempest Therapeutics - Enters $50 Million Common Stock Purchase Agreement With Lincoln Park
Tempest Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview
Brief: Tempest Announces Development Collaboration With Senlang Biotechnology For TPST-4003, A CD7-Targeted Next-Generation In Vivo CAR-T